Starton is a clinical-stage biotechnology company developing continuous delivery formulations of FDA-approved drugs to improve therapeutic profiles. The company focuses on delivering drugs at a steady rate to reduce peak blood concentrations, which Starton argues minimizes side effects while maintaining efficacy. Its lead program, STAR-LLD, is a continuous delivery system for lenalidomide, the active ingredient in the blood cancer drug Revlimid. Starton is developing two versions: STAR-LLD-SC, a subcutaneous infusion pump, and STAR-LLD-OCR, an oral controlled-release tablet. These candidates target patients with relapsed/refractory multiple myeloma and chronic lymphocytic leukemia. By reducing hematologic toxicities associated with standard oral lenalidomide, Starton aims to improve patient tolerability and adherence. The company utilizes the FDA’s 505(b)(2) regulatory pathway, allowing it to reference existing safety data for approved active ingredients to streamline development. Starton plans to commercialize its products after 2028, using generic active ingredients once original patents expire. Its strategy involves building a direct U.S. sales force targeting hematology oncology specialists and seeking international licensing arrangements. Starton is pre-revenue and dependent on equity financing to fund clinical trials, including current Phase 2 studies. The company prioritizes the oral tablet formulation as its primary commercial product while also exploring combinations with CAR-T therapies.